Cadila surges after US FDA clears Indian site
This article was originally published in Scrip
Shares of Cadila Healthcare spurted on Indian bourses in early trade on 17 July after the firm said that the US FDA had cleared its Moraiya facility in India, resolving issues raised in a warning letter issued by the regulator more than a year ago.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.